Novo Nordisk A/S reported DKK 309.1B of revenue over the trailing twelve months, +6.4% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: DKK 309.1B (to FY2025). Net Income: DKK 102.4B, trailing twelve months to FY2025. Free Cash Flow: DKK 59.0B, trailing twelve months to FY2025. Op Margin: 41%, trailing twelve months to FY2025.

NVONovo Nordisk A/S

HealthcareUSD

$45.17

$34.7652 weeks$61.72

Latest close: below its 200-day averageSep 8, 2026what changed →

NVO as reported

Novo Nordisk A/S reported DKK 309.1B of revenue over the trailing twelve months, +6.4% on the year before. 10 reported series are charted on this page, each one as filed.

DKK 309.1B

Revenue, trailing twelve months · to FY2025 · +6.4% against the twelve months before

Net Income: DKK 102.4B
Net Income · +1.4% year on year · trailing twelve months to FY2025
Free Cash Flow: DKK 59.0B
Free Cash Flow · −20% year on year · trailing twelve months to FY2025
Op Margin: 41%
Op Margin · trailing twelve months to FY2025

Every series Ryufin has for NVO, trailing twelve months
Series	Latest	Year on year	As of
Revenue	DKK 309.1B	+6.4%	FY2025
Net Income	DKK 102.4B	+1.4%	FY2025
EPS	DKK 23.03	+1.8%	FY2025
Gross Margin	81%	n/a	FY2025
Op Margin	41%	n/a	FY2025
Net Margin	33%	n/a	FY2025
ROE	53%	n/a	FY2025
ROA	19%	n/a	FY2025
ROIC	33%	n/a	FY2025
Free Cash Flow	DKK 59.0B	−20%	FY2025